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Abstract The efficiency of drug research and development
has paradoxically declined over the last decades despite
major scientific and technological advances, promoting
new cost-effective strategies such as drug repositioning by
systematic screening for new actions of known drugs. Here,
we performed a screening for positive allosteric modulators
(PAMs) at melanocortin (MC) receptors. The non-steroidal
anti-inflammatory drug fenoprofen, but not the similar
compound ibuprofen, presented PAM activity at MC3,
MC4, and MC5 receptors. In a model of inflammatory
arthritis, fenoprofen afforded potent inhibition while
ibuprofen was nearly inactive. Fenoprofen presented anti-
arthritic actions on cartilage integrity and synovitis, effects
markedly attenuated in Mc3r-/- mice. Fenoprofen dis-
played pro-resolving properties promoting macrophage
phagocytosis and efferocytosis, independently of
cyclooxygenase inhibition. In conclusion, combining
repositioning with advances in G-protein coupled receptor
biology (allosterism) may lead to potential new therapeu-
tics. In addition, MC3 PAMs emerged as a viable approach
to the development of innovative therapeutics for joint
diseases.
Keywords Inflammation  Arthritis  GPCR 
Drug repositioning  Resolution of inflammation
Introduction
In recent years, we have witnessed a steady and progressive
decline in productivity of the pharmaceutical industry
despite increased investments in R&D, leading to absence
of medicines active against the diseases of modern soci-
eties [38]. To obviate to this financial and medical problem,
drug repositioning has emerged as a new business model to
reduce developing timeframe, costs, and improve success
rates. Identification of new indications for old drugs (typ-
ically generics or drugs that failed approval for reasons
others than safety) has proven to be a feasible approach as
demonstrated, for instance, by the recent successful repo-
sitioning of thalidomide and sildenafil [31]. Compound
libraries containing approved drugs offer an opportunity for
systematic screening for potential new uses of existing
drugs, while simultaneously identifying novel candidates,
as it is accepted that drug repositioning by itself will not be
sustainable as sole development model for the medicines
required by western societies. However, merely by
including known molecules in drug screenings might not
represent a substantial improvement in success rate as the
complexity of disease mechanisms and still limited
understanding of whole biological systems (compared to
one-cell-at-a-time assays) are behind the unexpected lack
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of efficacy of promising drugs when tested in phase II and
III human trials.
The field of G-protein coupled receptors (GPCR), con-
sidered one of the largest classes for drug discovery, has
experienced a significant progress in recent years leading to
innovative approaches for the pharmacological exploitation
of these receptors including identification of biased ligands
and allosteric modulators. One of these promising targets in
the area of inflammation research is the melanocortin (MC)
receptors. Pharmacological strategies for targeting the MC
system are emerging as viable therapeutic approaches for a
number of diseases, including obesity, cachexia, vitiligo,
sexual dysfunction, dermatitis, and gouty arthritis [26].
Establishing receptor predominance in a given condition,
out of the five receptors identified (MC1–MC5), together
with development of selective agonists, is of paramount
importance to avoid off-target side effects. However, two
decades of extensive search for selective molecules using
classical orthosteric ligand approaches did not deliver any
successful drug. Contrasting with this lack of lead com-
pounds, there is a renewed interest in targeting the MC
system derived from the appreciation of a non-cortisol-
mediated properties of the MC peptide ACTH which
involve activation of peripheral MC receptors, including
MC3 [12, 26]. Activation of MC3 by its endogenous
ligands, ACTH and melanocyte-stimulating hormone
(MSH), attenuates inflammatory joint diseases in models
mimicking rheumatoid arthritis (RA) and gout. Treatment
of arthritic mice with the synthetic peptides DTrp8-cMSH
and AP214 reduces disease severity in the K/BxN serum
transfer model [29, 30, 34], while the natural peptides
aMSH, c2MSH, and MT-II (a stable derivative of aMSH)
inhibit urate crystal inflammation [4, 11]. Notwithstanding
this, the difficulty in achieving selective agonism has been
hampering full harnessing of MC biology for innovative
drug discovery programmes until now.
A promising strategy to attain selective activation of
closely related G-protein coupled receptors (GPCR) is
based on the development of allosteric ligands [1, 25, 33].
In contrast to orthosteric sites, where the natural ligands
bind, allosteric sites (i.e., sites spatially distinct from
endogenous ligands binding sites) display a higher degree
of sequence divergence, providing new opportunities for
the identification of selective compounds [9, 42]. Positive
allosteric modulators (PAMs) or allosteric enhancers,
potentiate receptor signaling in the presence of the
endogenous ligand thus maintaining both temporal and
spatial control, and may be burdened by fewer side effects
in view of their likely higher degree of selectivity [9, 42].
Recently, Pantel et al. performed a screening on potential
PAMs at MC4 to identify novel drugs for obesity with
reduced side-effects profile, yielding 62 positive modula-
tors [33].
We screened, here, a library of known small molecules
for PAM activity at MC3, identifying the marketed drug
fenoprofen (Fenopron, UK, Nalfon, US) as a positive
hit. Long known for its anti-arthritic activities and efficacy
in RA and osteoarthritis (OA) [17] fenoprofen is a non-
steroidal anti-inflammatory drug (NSAID) and inhibits
cyclooxygenase (COX) but as stated in the label, ‘‘its exact
mode of action is unknown’’. Here, we identify a new skill
of fenoprofen (fundamentally distinct from its known
COX-related mode of action) that may lead to further
functional studies as a unique tool compound, and perhaps
reconsider its use in conditions where the MC system has a
substantial role. In addition, our study reveals an important
contribution of MC3 in the therapeutic actions of feno-
profen in arthritis, providing proof of concept support to
the allosteric enhancing mode of targeting the MC system
for the treatment of inflammatory diseases.
Results
Fenoprofen is a positive allosteric modulator
at the MC3 receptor
Screening on a commercial library of known pharmaco-
logically active molecules ([1400 compounds) using
CHO cells stably expressing MC3 was run, using both an
‘‘agonist mode’’ (cAMP production) and a ‘‘PAM mode’’
(enhancement of cAMP production in the presence of a
suboptimal (*EC20) concentration of aMSH). Among the
most potent positive hits, the marketed NSAID fenoprofen
emerged as a PAM at human MC3. Fenoprofen did not
induce cAMP production when tested alone (Fig. 1a) but
induced a leftward-shift of the aMSH concentration
response in both human and mouse receptors (Fig. 1b).
Fenoprofen was not agonist at other MCRs (Supplemen-
tary Figure S1) but displayed PAM activity at human
MC3, MC4, and MC5 as well as mouse MC3, when aMSH,
ACTH, and Lys-c3MSH were used as endogenous ligands
(Table 1), indicating that the PAM activity of fenoprofen
was in general terms non-receptor and non-probe
selective.
Next, we addressed if MC receptor PAM activity was a
common feature of other COX inhibitors. We focused on
the NSAID family of propionic acid derivatives to which
fenoprofen belongs [17]. Of the seven COX inhibitors
tested, including ibuprofen, none potentiated melanocortin-
induced cAMP production (Supplementary Table S1 and
Supplementary Figure S2), indicating that the structural
and physicochemical requirements for COX inhibition do
not translate to MC3 PAM activity, with fenoprofen being
unique in its class for this bioaction.
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MC3 mediates the anti-arthritic actions
of fenoprofen
Since MC3 is emerging as a crucial receptor in controlling
the severity of inflammatory arthritis, we next studied its
potential involvement in the anti-arthritic actions of feno-
profen. The K/BxN serum transfer model of arthritis was
induced in both wild type (WT) and MC3 deficient mice
(Mc3r-/-). Arthritis developed normally in both strains
acquiring moderate to severe disease at days 4–5 (Fig. 2).
Pharmacological treatment of mice with fenoprofen or
ibuprofen (10 mg/kg twice per day from day 2; dose
selected from a pilot peritonitis—see Supplementary Fig-
ure S3) revealed distinct modulation of the disease. While
fenoprofen had a significant impact on clinical score, with
80% reduction at day 8 (Fig. 2a) and paw volume (*100%
reduction; Fig. 2b), ibuprofen was much less effective
affording only a moderate response on edema with no
effect on clinical score. Fenoprofen, but not ibuprofen, also
reduced disease incidence (Fig. 2c). A large majority of the
inhibitory properties of fenoprofen was lost in Mc3r-/-
mice (Fig. 2d, e), with residual effectiveness of *30%
both for clinical score and paw volume. All Mc3r-/- mice
treated with fenoprofen developed arthritis (Fig. 2f).
Identical dosing with Ibuprofen was not particularly
effective in this model, resulting in effects ranging from 5
to 30% inhibition for the majority of parameters tested.
Therefore, absence of Mc3r brings fenoprofen efficacy
comparable to that evoked by ibuprofen.
Gene expression analyses demonstrated a selective anti-
inflammatory action of fenoprofen with marked reduction
on monocyte marker Cd14, interleukin 1b (Il1b), RANK
ligand (Tnfsf11), cathepsin K (Ctsk), and metalloproteinase
9 (Mmp9) (Fig. 3a). Ibuprofen mildly reduced Il1b
expression albeit not significantly. Consistent with the
known effect of MC3 agonism on cell recruitment [14, 30],
the effect on Cd14 was absent in Mc3r-/- mice sug-
gesting that endogenous MC3 mediated this particular
action of fenoprofen. Interestingly, elevated levels of
osteoprotegerin (Tnfrsf11b), Ctsk, and Mmp9 in Mc3r-/-
vehicle-treated mice compared to WT suggest a defective
bone metabolism in mice lacking this receptor. Histologi-
cal analyses accounting for cell infiltration (H&E) and
cartilage integrity (safranin-O) (see Supplementary Fig-
ure S4 for scoring criteria) reiterated the potent inhibitory
actions of fenoprofen in the joints of WT but not in
Mc3r-/- mice (Fig. 3b). Ibuprofen did not exert tissue
protective actions.
These results indicate an important contribution of MC3
to the anti-arthritic actions of fenoprofen in vivo.
Local increase of endogenous melanocortin peptides
at inflammatory sites
Allosteric enhancers exert their biological effects only in
the presence of the endogenous agonist. Thus, we mea-
sured levels of melanocortin peptides in arthritic (day 8)
and naı¨ve joints. Interestingly, aMSH and ACTH were
significantly increased in the inflamed joints of arthritic
mice compared to non-arthritic mice (Fig. 4a), while
plasma levels remained stable with values within the
3–5 ng/ml range (Supplementary Figure S5). cMSH
levels were very low or not detectable in control joints.
The elevated levels of melanocortin peptides measured in
arthritic joints provide mechanistic support to the PAM
efficacy of fenoprofen. Moreover, measurements in
Mc3r-/- tissues demonstrated elevated values for cMSH
suggesting (1) the existence of a negative loop between
receptor expression and its high-affinity natural ligand
and (2) that the lack of effect of fenoprofen in this
genotype was not secondary to inadequate production of
the endogenous ligands.
Fig. 1 Allosteric modulatory activity of fenoprofen at the human
MC3 receptor. cAMP production was studied in human MC3
transfected CHO-K1 cells (GeneBLAzer beta-lactamase Reporter
Technology). Fenoprofen was tested for agonistic activity (a, agonist
mode) or in the presence of the agonist aMSH to address PAM
activity in human and mouse receptors (b, PAM mode)
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Fenoprofen exerts pro-resolving actions via MC3
We next studied if fenoprofen could produce known MC3-
mediated effects, such as increased phagocytosis by murine
peritoneal macrophages [30]. The latter cell type provides a
good model system for studying the effects of MC3 PAMs
since these cells produce endogenous peptides (Fig. 4b)
and express the melanocortin receptors MC1,3,5 [30]. As
reported in Fig. 4, fenoprofen promoted phagocytosis of
bacteria (Fig. 5a, e) and apoptotic neutrophils (Fig. 5b, f),
the latter process often termed efferocytosis. The potenti-
ation of phagocytosis by fenoprofen was marked and
followed a bell-shaped curve, commonly observed for
melanocortin activation [13, 14], with 0.1 lM being the
most active concentration. Of interest fenoprofen was
inactive when Mc3r-/- cells were used (Fig. 5a, b),
although Mc3r-/- cells in vitro produced similar levels of
endogenous agonists (Fig. 4b).
To exclude COX inhibition as part of the pro-phagocytic
actions of fenoprofen, aspirin (ASA) was chosen as a
control for the next study as it inhibits COX irreversibly
and it is chemically unrelated to fenoprofen. While the pro-
phagocytic and pro-efferocytic effect of fenoprofen was
confirmed, ASA did not have any effect on phagocytosis
(Fig. 5c). In a subsequent set of experiments, the pro-
phagocytic effects of fenoprofen were assayed 20 min after
pre-incubation with ASA (50 lM) to irreversibly block
COX enzymes. As shown in Fig. 5d, the pro-phagocytic
Table 1 Positive allosteric modulator activity of fenoprofen at melanocortin receptors
Drug Receptor
mMC3 hMC3
(*) hMC4 hMC5
NDP-aMSH pEC50 Log shift pEC50 Log shift pEC50 Log shift pEC50 Log shift
?0 lM Fen 9.78 9.40 10.49 8.98
?3 lM Fen 9.86 0.08 9.51 0.11 – 8.97 -0.01
?10 lM Fen 9.76 -0.02 9.58 0.19 10.47 -0.02 9.06 0.08
?30 lM Fen 9.71 -0.07 9.66 0.26 10.38 -0.11 8.99 0.01
Drug Receptor
mMC3
(*) hMC3
(*) hMC4
(*) hMC5
(*)
aMSH pEC50 Log shift pEC50 Log shift pEC50 Log shift pEC50 Log shift
?0 lM Fen 8.33 7.58 8.38 6.64
?3 lM Fen 8.42 0.10 7.67 0.09 – 6.75 0.11
?10 lM Fen 8.58 0.25 7.92 0.34 8.80 0.41 6.89 0.25
?30 lM Fen 8.86 0.53 8.30 0.71 9.11 0.73 7.22 0.58
Drug Receptor
mMC3
(*) hMC3
(*) hMC4
(*) hMC5
(*)
ACTH pEC50 Log shift pEC50 Log shift pEC50 Log shift pEC50 Log shift
?0 lM Fen 8.69 8.19 8.76 6.78
?3 lM Fen 8.72 0.04 8.29 0.10 – 6.84 0.06
?10 lM Fen 8.85 0.16 8.57 0.38 9.09 0.33 7.03 0.25
?30 lM Fen 9.03 0.34 8.87 0.68 9.25 0.48 7.29 0.51
Drug Receptor
mMC3 hMC3
(*) hMC4
(*) hMC5
(*)
Lys-c3MSH pEC50 Log shift pEC50 Log shift pEC50 Log shift pEC50 Log shift
?0 lM Fen 9.19 8.80 7.33 6.13
?3 lM Fen 9.24 0.05 8.89 0.09 – 6.31 0.18
?10 lM Fen 9.30 0.11 9.09 0.29 7.48 0.14 6.61 0.48
?30 lM Fen 9.27 0.08 9.35 0.55 7.72 0.39 6.80 0.67
Leftward log shift of the peptide ligand and EC50 values are reported at murine MC3 and human MC3,4,5 receptors (*indicates PAM activity)
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Fig. 2 Antiarthritic effect of
fenoprofen in the K/BxN serum
transfer model. Arthritis was
induced on wild type (a–c) and
Mc3r-/- (d–f) mice by two i.p.
injections of arthritogenic serum
on day 0 and 2.
Pharmacological treatments
(fenoprofen, Fen, and ibuprofen,
Ibu: 10 mg/kg; vehicle: PBS)
were administered i.p. twice
daily from day 2. Non-arthritic
mice were used as controls
(Ctrl). Clinical score (a, d), paw
volume (b,e) and disease
incidence (c,f) were recorded
over 8 days. Data are
mean ± SEM of n = 5;
*p\ 0.05 ANOVA followed by
Bonferroni multiple comparison
test
Fig. 3 Gene expression and histological changes in arthritic joints.
a Gene expression was analyzed in ankles from wild type (WT, black
bars) and Mc3r-/- (white bars) mice as collected at day 8, and
expressed as fold change with respect to non-arthritic control mouse
joints. Groups correspond to vehicle (Veh), fenoprofen 10 mg/kg
(Fen), and ibuprofen 10 mg/kg (Ibu). Data are mean ± SEM of
n = 5; *p\ 0.05 two-way ANOVA followed by Bonferroni multiple
comparison test of veh vs. drugs, #p\ 0.05 WT vs. Mc3r-/-.
b Ankle sections (4 lm) were stained with hematoxylin and eosin
(H&E) and fast green and safranin-O. Sections were graded from 0
(no disease) to 3 (severe) based on the degree of synovitis (purple
staining in the H&E sections) and cartilage erosion (loss of red
coloration in the safranin-O sections). C cell infiltrate, B bone,
M muscle, F fat. The sum of H&E and safranin-O scores are
represented in the left graph. Data are mean ± SEM of n = 5;
p\ 0.05 drug vs. Veh (*), or Veh vs. Ctrl (#) ANOVA followed by
Bonferroni multiple comparison test
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effect of fenoprofen was retained even in experimental
settings with cells pre-treated with ASA.
These results, together with the experiment conducted
with Mc3r-/- cells (Fig. 5a, b), indicate that this receptor
genuinely mediates specific pro-resolving actions of
fenoprofen.
Discussion
The so-called Eroom’s law [38] refers to the decline in phar-
maceutical R&D efficiency despite marked improvements in
technology, where the cost of developing a new drug roughly
doubles every 9 years. However, some estimates suggests the
cost of repositioning a drug may drop from $2–3 billion to
$300million, leading to an increase in newcompanies entirely
focused on this strategy [31]. Drug repositioning is proven
attainable as several drugs have already been repurposed—
e.g., the antihypertensive minoxidil for hair loss, or the anti-
malarial hydroxychloroquine for arthritis—although in many
cases these novel indications are discovered by serendipity.
However, the advance strategy resides in incorporating
repositioning as an active systematic approach to drug dis-
covery, for instance, by including known drugs in compound
screening programmes.
Fig. 4 Production of endogenous melanocortin peptides in arthritic
mouse joints and primary macrophages. a Wrists joints from K/BxN
arthritic mice (wild type and Mc3r-/-) were collected at day 8 and
protein extracts prepared on RIPA buffer. The melanocortin peptides
aMSH, cMSH, and ACTH were determined by enzyme immunoassay
following manufacturers’ protocol. b Biogel-elicited macrophages
were collected from mice (wild type and Mc3r-/-) 4 days after an
i.p. injection with 1 ml of 2% biogel. Cells were cultured in vitro
during 24 h in 10% FCS-RPMI. Supernatants were analyzed for
aMSH, cMSH, and ACTH levels by enzyme immunoassay. Data are
mean ± SEM of n = 5; p\ 0.05 ANOVA followed by Bonferroni
multiple comparison test K/BxN vs. Ctrl (*) or WT vs. Mc3r-/- (#)
Fig. 5 Pro-phagocytic actions of fenoprofen. Biogel-elicited peri-
toneal macrophages from wild type (WT) and Mc3r-/- mice were
incubated with: a pHrodoTM Red E. coli for 20 min and analyzed by
flow cytometry, or b apoptotic human neutrophils for 1 h and
analyzed by myeloperoxidase (MPO) staining and cell counting.
c Fenoprofen (Fen) and acetylsalicylic acid (ASA) were added 30 min
prior addition of E. coli. d ASA was added 20 min before fenoprofen,
and E. coli was added after 30 min incubation with fenoprofen.
Images in e show that fluorescence develops specifically on ingested
bacteria. Images in f show neutrophils (dark brown MPO staining)
ingested by macrophages (efferocytosis). Data are mean ± SEM of
n = 3; *p\ 0.05 ANOVA followed by Bonferroni multiple compar-
ison test
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Targeting the melanocortin system is emerging as a
potential therapeutic approach to treat a variety of
inflammatory conditions. This approach is corroborated not
only by the large amount of scientific literature
[5, 15, 32, 40], but also by the clinical evidence obtained
from the use of ACTH in clinical practice since its approval
in 1952. This natural melanocortin peptide has been used to
treat gouty arthritis for more than 60 years and it is cur-
rently included in the ACR guidelines for the treatment of
acute attacks of this disease of the joints [22, 36]. Acthar
Gel and Synacthen Depot are the formulations currently
available and conditions such as RA, multiple sclerosis,
inflammatory bowel disease, and dermatitis fall within their
FDA- and EMA-approved indications [26]. With the
exception of gouty arthritis and/or specific regions using
clinical evidence-based practice, ACTH is otherwise sel-
dom used. The main reason for its limited use in patients is
related to the persistent activation of MC2, which leads to
the excessive production of cortisol with the instauration,
over time, of substantial side effects.
However, the development of new MC drugs as an anti-
inflammatory strategy is experiencing a renewed interest
due to the discovery of MC3 activation as a crucial pathway
mediating the anti-arthritic actions of ACTH. This ‘‘ACTH
renaissance’’ applies to conditions like multiple sclerosis
[2, 37], proteinuric nephropathies [16], and lupus [24],
where the anti-inflammatory properties of ACTH might
also be mediated through the peripheral, or non-adrenal,
MC system. On the other hand, lack of receptor selectivity
achieved by currently developed MC molecules may limit
their clinical development.
While challenging, the complexity of GPCR biology
represents a source of innovation in drug discovery. For
example, we recently characterized a small molecule that
activated only a subset of signaling cascades associated
with MC3 (a process known as GPCR-biased signaling)
with the functional consequences of retaining full anti-in-
flammatory effect while preventing the unwanted
melanogenic effects [28]. In the present work, we exploit
the existence of GPCR-allosterism as an opportunity to
achieve selectivity among highly conserved receptor fam-
ilies, as it is the case within the MC system. Two reports
have already identified positive and negative allosteric
modulators to MC4 and MC5, respectively [18, 33]. In
more general terms, the utility of PAMs as a therapeutic
strategy in the clinic is exemplified by diazepam (Val-
ium), which potentiates the activity of GABA.
In our study, we performed a compound screening on a
commercially available library aiming to identify novel
agonists and/or PAMs of the human MC3. In this way, we
integrated a drug repositioning approach (using a library
containing known drugs) with the exploitation of novel
capabilities of GPCRs like allosteric enhancing.
Intriguingly, the anti-inflammatory drug fenoprofen, a
COX inhibitor with high efficacy in RA, was identified as a
potent hit. This PAM activity was, however, not specific
for MC3, as the potency of aMSH, ACTH, and Lys-c3MSH
in MC4 and MC5 transfected cells was also increased.
Although fenoprofen did not display receptor selectivity, as
a PAMs it could offer a second wave of functional selec-
tivity by acting only when endogenous ligands are
expressed. From our perspective, the novel aspect of our
findings resides in the fact that a drug with indication for
RA and OA might be engaging the melanocortin system,
providing proof-of-concept for MC3 targeting as a treat-
ment of joint diseases.
A growing body of evidence supports the role of mel-
anocortins and MC3 in joint inflammation. Melanocortin
drugs can reduce cytokine levels, prevent immune cell
infiltration, reduce joint inflammation, modulate nitric
oxide production, and promote pro-resolving actions like
efferocytosis [11, 30, 34, 41]. Many of these parameters
were also affected by fenoprofen when tested in experi-
mental arthritis. The target cells of MC agonists, relevant in
the context of inflammation, are immune cells such as
macrophages [4] and neutrophils [6] as well as non-im-
mune cells in the joint. For example, MC3 is particularly
important for osteoclast biology, as these cells show
increased resorptive activity when derived from Mc3r-/-
macrophages compared to WT cells [34]. Osteoblasts can
also be targeted by melanocortins as shown for ACTH [43],
while chondrocyte anabolic activity can be stimulated by
MC agonists [20, 21], counteracting the detrimental effects
of pro-inflammatory cytokines.
We provide evidence for this fundamental role of MC3
with further in vivo and in vitro experiments. In the model
of K/BxN serum transfer arthritis [10], at 10 mg/kg daily,
fenoprofen reduced clinical score by 80% in WT mice,
while this effect was markedly attenuated in animals
lacking MC3. Under these conditions, fenoprofen reduced
disease incidence to 60% compared to 100% in vehicle-
treated mice, an effect only observed in WT mice. These
results suggest an important contribution of the receptor
MC3 in the anti-arthritic actions of fenoprofen. We note
here that, among the propionic acid COX inhibitors,
fenoprofen is the only one associated with body weight
loss, at least upon prolonged administration [17]. We rea-
son this effect can be secondary to the MC4 activation we
describe here: this compound—likely to cross the blood
brain barrier—might activate MC4 in multiple brain
regions to reduce appetite [3]. Another adverse reaction
reported for fenoprofen is increased sweating (*5% inci-
dence), which would be consistent with MC5 activation on
exocrine glands [19].
Presence of endogenous MC peptides in the arthritic
joints of K/BxN serum-treated mice is remarkable since
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fenoprofen allosteric enhancing activity would manifest
only in their presence. At peak of arthritis, it was important
to quantify a selective increase in ACTH and aMSH levels
in the joints, with no concomitant changes in blood levels.
Of note, it has been documented that endogenous MC
peptides levels are increased in human synovial fluid from
RA patients [7].
It was then crucial to compare the contribution of COX
inhibition to the PAM activity of fenoprofen; hence, we
tested the ability of a panel of propionic acid derivative
NSAIDs to left-shift the cAMP concentration response
curve. None of the drugs tested, apart from fenoprofen and
its calcium salt, displayed PAM activity. This suggests on
one hand, the existence of specific structural and confor-
mational requirements for a small molecule MC3 PAM
and, on the other hand, no associated requirement for COX
inhibition to achieve this specific enhancing property.
In the final part of the study, we determined if feno-
profen could evoke MC3-dependent pro-resolving
functions [35, 39], properties described for the melano-
cortin pan-agonist AP214 [30]. The pro-phagocytic and
pro-efferocytic actions of fenoprofen were absent when
tested with macrophages from Mc3r-/- mice. In these
controlled settings aspirin and ibuprofen were inactive
providing strong indication that these biological effects are
unrelated to COX inhibition.
An important control that could not be run was the
assessment of the contribution of COX inhibition to the
anti-arthritic effects of fenoprofen because in the K/BxN
serum-induced model of arthritis, mice lacking the COX-1
isoform do not develop disease [8], whereas selective
COX-2 inhibitors are inactive. However, the in vitro
phagocytosis assays allowed us to address this issue, since
aspirin was ineffective on its own and did not affect the
pro-phagocytic properties of fenoprofen.
In conclusion, MC receptors represent novel targets for
the development of innovative therapies for RA and other
inflammatory diseases: targeting MC3 using PAMs con-
stitutes a viable and biologically effective means to reduce
synovial inflammation. This work also provides the first
link between MC3 targeting and anti-arthritic efficacy in
man: fenoprofen, in contrast to other propionic acid
derivatives, is particularly effective in RA and OA and here
we show that activity at MC receptors, only achieved by
this molecule, might explain this therapeutic advantage
over other NSAIDs. Our approach also reflects the poten-
tial of repositioning screening strategies, to rediscover new
mechanisms and actions for old drugs. These results may
pave the way for further identification and development of
new MC3 allosteric enhancers, and possibly also for MC1
and/or MC5, as discussed above, to modulate host inflam-
matory responses in chronic pathologies.
Materials and methods
Compound library screening
The compound screening was performed on the commer-
cially available library NINDS (National Institute of
Neurological Disorders and Stroke) containing [1400
drugs using a single concentration of test compound
(10 lM). The HTRF cAMP assay (Cisbio Bioassays,
Codolet, France) was performed on CHO cells stably
expressing the human MC3 (GeneBLAzer
 beta-lactamase
Reporter Technology, Invitrogen, Paisley, UK) according
to manufacturer’s protocol. Human MC1, MC4, MC5
(SNAP-tag Taglite Technology, HEK293 cells; Cisbio
Bioassays), human MC2 (GeneBLAzer
, CHO cells) and
mouse MC3 (FLAG-tag, HEK293 cells; Genecopoeia,
Source BioScience, Nottingham, UK) were used to study
selectivity and ortholog activation. Drugs were tested for
agonistic activity, in which the HTRF cAMP accumulation
assay was performed with 10-point 0.5 log serial dilutions
(0.316–10 lM) and for their ability to potentiate the effect
of the agonist Lys-c3MSH (Cambridge Biosciences,
Cambridge, UK) used at EC20. Leftwad-shifts assays were
then conducted on positive hits using a concentration
response curve of Lys-c3MSH (0.01–1 lM) in the absence
or presence (0.1–100 lM) of test compound.
Animals
7–8 weeks old, male, C57BL/6J wild-type (WT) mice were
purchased from Charles River (Kent, UK). Mc3r-/- mice
were a generous gift of Dr Chen (Merck Laboratories). All
animal studies were approved and performed under the
guidelines of the Ethical Committee for the Use of Ani-
mals, Barts and The London School of Medicine and Home
Office Regulations (Guidance on the Operation of Animals,
Scientific Procedures Act, 1986).
Zymosan-induced peritonitis
Peritonitis was induced by the injection of 1 mg zymosan
A (Sigma-Aldrich, Poole, UK) i.p. in 0.5 ml sterile PBS.
Animals (4 per group) were pre-treated with fenoprofen or
vehicle (PBS) administered i.p. 30 min before zymosan
injection. Four hours later, mice were killed by CO2
exposure and peritoneal cavities washed with 4 ml of ice
cold PBS containing 3 mM EDTA and 25U/ml heparin.
100 ll aliquots of lavage fluids were stained with Turk’s
solution (0.01% crystal violet in 3% acetic acid) and cells
counted on a Neubauer haemocytometer or stained with
conjugated antibodies for Ly-6G (FITC) and F4/80 (APC)
used in 1:100 dilution. Corresponding isotype controls and
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blocking antibody anti-mouse CD16/32 were used. All
antibodies were purchased from eBioscience (Hatfield,
UK). Flow cytometry was performed in the BD
FACSCaliburTM.
K/BxN serum transfer arthritis model
Arthritis was induced with two i.p. injections of 100 ll of
K/BxN serum on days 0 and 2. Disease was monitored
daily until day 8 by assessing the paw volume using a
plethysmometer (Ugo Basile, Comerio, Italy), disease
incidence (mice showing any signs of arthritis) and clinical
score (score per paw: 0 = no signs of inflammation;
1 = subtle inflammation, localized; 2 = easily identified
inflammation but localized; 3 = evident inflammation, not
localized; max score = 12 per mouse) [23]. Pharmaco-
logical treatments were administered i.p. twice daily from
day 2 until the end of the experiment. Fenoprofen calcium
salt hydrate and ibuprofen sodium salt were obtained from
Sigma-Aldrich (Poole, UK).
RNA extraction, cDNA synthesis, and real time-PCR
Total RNA was extracted using TRIzol (Invitrogen,
Paisley, UK) following manufacturer’s instructions.
cDNA was synthesized using 1ug of RNA with the
SuperScript III Reverse Transcriptase (Invitrogen, Pais-
ley, UK). Real time-PCR was performed in duplicates,
with 2 ll cDNA diluted 1/5, 1 ll primers and Power
SYBR Green PCR Master Mix (Applied Biosystems,
Warrington, UK), using the ABI Prism 7900HT Sequence
Detection System. Quantitect primers (QIAGEN, Craw-
ley, UK) used are the following: Hprt (QT00166768),
Cd14 (QT00246190), Il1b (QT01048355), Tnfsf11
(QT00147385), Tnfrsf11b (QT00106757), Ctsk
(QT00150703) and Mmp9 (QT00108815). Dissociation
step was always included to confirm the absence of un-
specific products. Fold change was calculated as 2-DDCt
using Hprt as reference gene.
Enzyme immunoassay
Melanocortin peptide levels were determined by enzyme
immunoassay (EIA) in plasma and proteins extracts pre-
pared from the right upper limbs homogenized in RIPA
buffer using the Precellys24 tissue homogenizer (Stretton
Scientific, Derbyshire, UK) and hard tissue grinding beads.
Alpha-MSH, gamma2-MSH, and ATCH EIA kits (Phoenix
Pharmaceuticals, Karlsruhe, Germany) were used follow-
ing manufacturers protocols.
Histological analyses
Joints were fixed with 4% neutral buffered formalin,
decalcified with 10% formic acid and paraffin embedded.
Sections (4 lm) were stained with hematoxylin and eosin
(H&E) and fast green and safranin-O. Sections were graded
from 0 (no disease) to 3 (severe) based on the degree of
synovitis and cartilage erosion [34].
Escherichia coli phagocytosis by macrophages
Biogel-elicited peritoneal macrophages were obtained from
wild type and Mc3r-/- mice 4 days after an i.p. injection
with 1 ml of 2% biogel (BioRad, Hemel Hempstead, UK)
[27]. 1 9 106 cells were plated in 24-well plates and pre-
treated with corresponding drugs for 30 min before addi-
tion of bacteria (pHrodoTM Red E. coli Bioparticles
Conjugate, Invitrogen, Paisley, UK). After 20 min, non-
ingested bacteria were washed and cells incubated for
further 30 min to allow fluorescence to develop. Cells were
trypsinized and analyzed by flow cytometry (BD
FACSCaliburTM, FL-2).
Phagocytosis of apoptotic neutrophils
by macrophages
Experiments using healthy volunteers were approved by the
local research ethics committee (P/00/029 East London and
The City Local Research Ethics Committee 1). Informed
written consent was provided according to theDeclaration of
Helsinki. Neutrophils were isolated from human blood using
the double-density gradient with Histopaque 10771 and
11191 following manufacturer’s protocols [27]. Cells were
incubated overnight in 10% FCS to let neutrophils undergo
spontaneous apoptosis. 0.5 9 106 biogel-elicited macro-
phages were plated in 24-well plates and pre-treated with
corresponding drugs for 30 min before addition of apoptotic
neutrophils. After 1 h, macrophages were washed and fixed
with 2.5% glutaraldehyde. The myeloperoxidase (MPO)
assay was performed by adding 0.1 mg/ml of o-dianisidine
dihydrochloride (Sigma-Aldrich, Poole, UK) and 0.03% (v/
v) hydrogen peroxide. After 1 h, cells were washed and
analyzed by lightmicroscopy,with three randomfields being
acquired per well.
Statistics
Data are reported as mean ± SEM of n animals or tissue
samples or, for in vitro experiments, performed in duplicate
or triplicate from at least three distinct experiments. A
p value\0.05 was taken as significant.
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